Table 1 Sample descriptives
From: Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades
Variables | N | % | Study duration (in years) |
|---|---|---|---|
Company | 30 | ||
Clinical trials | 13,589 | 100 | |
Study phase | |||
Phase 1 | 4998 | 36.77 | 1.04 |
Phase 2 | 2800 | 20.60 | 2.32 |
Phase 3 | 4219 | 31.04 | 2.56 |
Phase 4 | 1572 | 11.56 | 1.87 |
Indications | |||
CARD | 697 | 5.13 | 1.59 |
DERM | 367 | 2.70 | 1.83 |
HAEM | 264 | 1.94 | 2.13 |
HORM | 28 | 0.21 | 1.84 |
INFEC | 1364 | 10.04 | 1.88 |
META | 1993 | 14.67 | 1.52 |
MUSCO | 389 | 2.86 | 2.21 |
NEURO | 1716 | 12.63 | 1.86 |
ONCIM | 2720 | 20.02 | 3.72 |
PARA | 0 | 0.00 | |
RESP | 969 | 7.13 | 1.27 |
SENS | 278 | 2.05 | 1.00 |
URO | 359 | 2.64 | 1.82 |
VAR | 225 | 1.66 | 1.32 |
Healthy volunteers (Phase 1) | 2220 | 16.34 | 0.37 |